Skip to main content

Menu

British National Formulary September 2024 Update

This update contains 7 significant changes, 2 dose changes, 1 new preparation, 2 deleted monographs and 2 deleted preparations.

Significant Changes:

  • Cabergoline: updated important safety information.
  • Carbamazepine (Tegretol® 100 mg/5 mL Liquid): temporary stock-out and update to posology (reduction of maximum daily dose) [MHRA/CHM advice].
  • Drugs that cause sedation and drugs with CNS depressant effects: pharmacodynamic effects drug groups combined and renamed as drugs with CNS effects; see Interactions.
  • Hyperkalaemia: updated guidance on management.
  • Salbutamol: new indication and dose for moderate to severe hyperkalaemia.
  • Topiramate (Topamax®): introduction of new safety measures, including a Pregnancy Prevention Programme [MHRA/CHM advice].
  • Warfarin: be alert to the risk of drug interactions with tramadol [MHRA/CHM advice] (advice in warfarin sodium and acenocoumarol; see example in warfarin sodium).

Dose Changes:

  • Lebrikizumab [update to dosing].
  • Rosuvastatin [update to dose adjustments due to interactions with belumosudil].

New Preparations: Ivermectin.

Deleted Monographs: Colecalciferol with calcium phosphate; Porfimer sodium.

Deleted Preparations: Creon 40000® [pancreatin]; Pancrease HL® [pancreatin].”